Paper · 42876643
Two-year dynamic risk stratification and adjuvant radioiodine efficacy in initial non-distant metastatic papillary thyroid carcinoma harboring TERT promoter mutations.
Deng XZ and 9 others. Front Oncol, 2026.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Two-year dynamic risk stratification and adjuvant radioiodine efficacy in initial non-distant metastatic papillary thyroid carcinoma harboring TERT promoter mutations. Papers, record 42876643. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42876643
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Two-year dynamic risk stratification and adjuvant radioiodine efficacy in initial non-distant metastatic papillary thyroid carcinoma harboring TERT promoter mutations.
- Journal
- Front Oncol
- Year
- 2026
- Publication types
- Journal Article
- Revised in PubMed
- 2026-10-16
Source PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References39
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25,583,906 | TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma. | Eur J Endocrinol | 2015 | https://conductscience.org/library/papers/25583906 | PubMed |
| 2 | 33,922,635 | Genetic Determinants for Prediction of Outcome of Patients with Papillary Thyroid Carcinoma. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/33922635 | PubMed |
| 3 | 39,557,834 | Mechanistic basis of atypical TERT promoter mutations. | Nat Commun | 2024 | https://conductscience.org/library/papers/39557834 | PubMed |
| 4 | 31,820,047 | Clinicopathologic risk factors of radioactive iodine therapy based on response assessment in patients with differentiated thyroid cancer: a multicenter retrospective cohort study. | Eur J Nucl Med Mol Imaging | 2020 | https://conductscience.org/library/papers/31820047 | PubMed |
| 5 | 37,532,521 | TERT promoter mutations in thyroid cancer. | Endocr J | 2023 | https://conductscience.org/library/papers/37532521 | PubMed |
| 6 | 33,117,686 | Clinical, Pathological, and Molecular Characteristics Correlating to the Occurrence of Radioiodine Refractory Differentiated Thyroid Carcinoma: A Systematic Review and Meta-Analysis. | Front Oncol | 2020 | https://conductscience.org/library/papers/33117686 | PubMed |
| 7 | 40,844,370 | 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer. | Thyroid | 2025 | https://conductscience.org/library/papers/40844370 | PubMed |
| 8 | 26,969,876 | Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients. | Cancer | 2016 | https://conductscience.org/library/papers/26969876 | PubMed |
| 9 | 29,128,176 | Back so soon? Is early recurrence of papillary thyroid cancer really just persistent disease? | Surgery | 2018 | https://conductscience.org/library/papers/29128176 | PubMed |
| 10 | 24,891,169 | Update on differentiated thyroid cancer staging. | Endocrinol Metab Clin North Am | 2014 | https://conductscience.org/library/papers/24891169 | PubMed |
1 to 10 of 39
See all 39 referencesCited by0
The papers in our copy of PubMed whose reference list names this one, newest first.
None in this release.
Genes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42876643
GET https://conductscience.org/api/papers/v1/42876643/references?page=2